학술논문
Merrill delights in A$1.75bn CSL equity record breaker.
Document Type
Article
Author
Source
Subject
*Going private (Securities)
*Mergers & acquisitions
*Corporate finance
*Finance
*
*
*
Language
ISSN
0952-7036
Abstract
This article focuses on the successful accelerated global share placement completed by life sciences firm CSL in August 2008 to help finance its bid for American firm Talecris Biotherapeutics. CSL will finance the remainder of the purchase with cash and a bridging loan from Merrill Lynch. Merrill launched the accelerated global bookbuild and initially aimed to raise A$1.685 billion (bn). The offer closed at 9am on August 14, three hours early, and reached A$1.75bn. International buyers accounted for around 40% of the book.